When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Persistent depressive disorder

最后审阅: 26 Feb 2026
最后更新: 25 Jul 2023

小结

定义

病史和体格检查

关键诊断因素

  • chronic mood disorder lasting greater than 2 years
  • depressive symptoms present for most of the day, most days
  • no periods of euthymia in the past 2 years (1 year for children or adolescents)
  • symptoms of major depression may be continuously present for 2 or more years
完整详情

其他诊断因素

  • no symptoms of mania/hypomania or schizophrenia
  • absence of underlying medical conditions, medication use, or substance abuse that could cause the mood disorder
  • fatigue or low energy
  • low self-esteem
  • poor concentration or difficulty making decisions
  • feelings of hopelessness
  • poor appetite or overeating
  • sleep disturbance
完整详情

危险因素

  • positive family history
  • female sex
完整详情

诊断性检查

首要检查

  • medical evaluation
  • CBC
  • thyroid function tests
  • metabolic panel
  • vitamin D
  • Patient Health Questionnaire (PHQ-9)
  • Beck Depression Inventory (BDI)
  • Quick Inventory of Depressive Symptoms (QIDS)
完整详情

需考虑的检查

  • vitamin B12
  • urine test
  • ECG
完整详情

治疗流程

急症处理

all patients

撰稿人

作者

David J. Hellerstein, MD
David J. Hellerstein

Professor of Clinical Psychiatry

Columbia University Medical Center

Director, Depression Evaluation Service

New York State Psychiatric Institute

New York

NY

利益声明

DJH has received research grants (through the Research Foundation for Mental Hygiene) from Compass Pathways, Relmada, Marinus, Intracellular Therapies, Beckley Foundation, and from Velocity Foundation (through Columbia University). DJH serves on scientific advisory board for Reset Pharmaceuticals. DJH has received royalties from Johns Hopkins University Press, and Columbia University Press.

鸣谢

Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this topic.

利益声明

DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this topic.

同行评议者

Dean F. MacKinnon, MD

Associate Professor

John Hopkins University

Baltimore

MD

Раскрытие информации

DK declares that he has no competing interests.

James H. Kocsis, MD

Professor

Weill Cornell Medicine

New York

NY

Раскрытие информации

JK has professionally collaborated with the authors.

Neil Nixon, BSc, MMedSci, MBBS, FRCPsych

Associate Professor in Psychiatry

Institute of Mental Health

University of Nottingham

Nottingham

UK

Раскрытие информации

NN is a member of the current NICE GDG for depression in adults. NN has met with Jansen in a non-remunerative capacity. He has various research collaborations including a funded trial and is author on a number of papers.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

Blanco C, Okuda M, Markowitz JC, et al. The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010 Dec;71(12):1645-56.Полный текст  Аннотация

Devanand DP, Adorno E, Cheng J, et al. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004 Mar;78(3):259-67. Аннотация

Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. J Clin Psych. 2011 Apr;72(4):509-14. Аннотация

Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683-96. Аннотация

Pedrelli P, Iovieno N, Vitali M, et al. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct;31(5):582-6. Аннотация

Bauer M, Severus E, Köhler S, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности